Endocrine Abstracts

Background: Recent studies show that Infliximab (IFX), an antibody against tumour necrosis factor α (TNFα), may improve growth in children with Crohn’s disease (CD). These studies have not adequately addressed the concomitant factors such as medication, nutrition and puberty that may also improve growth.Methods: Retrospective study of 22 children (13 M) with CD, median age at start of IFX 13.2 years (7.4, 16.1) with auxology at 6 months be...

Background: Growth retardation and pubertal delay is frequently encountered in children with inflammatory bowel disease (IBD). There are currently no published data on sitting height (SH), subischial leg length (SILL)and growth rates in relation to pubertal status in these children.Objective: To assess skeletal disproportion and growth rates in children with IBD.Methods: Retrospective study of 40 children (32M):35 Crohn’s dise...

Background: Recent studies show that infliximab (IFX), an antibody against tumour necrosis factorα (TNFα), may improve growth in children with Crohn’s disease (CD). These studies have not adequately addressed the concomitant factors such as medication, nutrition and puberty that may also improve growth.Methods: Retrospective study of 22 children (13M) with CD, median age at start of IFX 13.2 years (7.4, 16.1) with auxology at 6 months befo...

Background: Children with inflammatory bowel disease (IBD) may suffer from growth and pubertal delay.Objective: To assess pubertal status and growth in a group of boys with IBD before (T+0) and 6 months after (T+6) initiation of testosterone therapy.Methods: Retrospective study of boys with IBD undergoing pubertal induction. Height (Ht) and pubertal status were obtained at T+0 and T+6. Markers of disease activity and data on concom...

Background: Recombinant human GH (rhGH) may improve bone mass in paediatric inflammatory bowel disease (IBD).Objective: To investigate rhGH on bone and body composition in paediatric IBD.Method: Bone biomarkers were evaluated in 12 children, 11CD (10M), median age 14.4 year (8.9, 16.2) who received rhGH (0.067 mg/kg per day) as part of a 6 months RCT. Eight received rhGH for 24 months and had DXA evaluation. Results were reported a...

Background: Delayed puberty and related problems with growth and body image in Crohn’s disease (CD) and ulcerative colitis (UC) have rarely been quantified.Methods: A longitudinal prospective observational study of children with IBD who had anthropometric and puberty data at 0 and 6 months. Of 50 recruited, there were 15 boys (CDM) and 20 girls (CDF) with CD and ten boys (UCM) and five girls (UCF) with UC. The four groups had a median age at 0 month...

Background: Puberty is understood to be commonly effected in adolescents with Crohn’s Disease (CD) and ulcerative colitis (UC). However, the extent of this effect and related problems with growth, have rarely been quantified.Objective: To determine the impact of CD and UC on pubertal growth.Methods: Retrospective study of 148 children with IBD (casenotes available, 135) who fulfilled the criteria for describing growth spurt pa...

Background: Although colonic polyps are associated with states of GH excess, no association with gastric polyps has been reported. We describe 2 patients who were treated with rhGH for non-GH deficient growth disorders and who were subsequently found to have gastric polyps.Patient 1: A girl aged 13.6 year with short stature was found to have Turner’s syndrome in the course of being investigated for abdominal pain, diarrhoea and rectal bleeding. Endo...

Background and aim: It is often proposed that growth retardation in IBD is associated with a state of growth hormone resistance but published data on the GH-IGF1 axis are scarce. We describe the results of routine clinical assessment of this axis in a group of such children.Methods: A retrospective study of 24 children with IBD (22 CD, 2 UC) with growth retardation and/or pubertal delay who underwent insulin tolerance test (ITT) following referral to the...

Background: A recent RCT of rhGH in IBD over 6 months showed that improvement in linear growth was associated with a reduction in insulin sensitivity.Objectives: To investigate the effects of prolonged rhGH on growth and glucose homeostasis in children with IBD.Patients and methods: Eleven children (10CD/1UC) (9 m) with a median age of 14.7 years (range, 8.9, 16.2) who received rhGH (0.067 mg/kg per day) as part a 6-month RCT were ...